A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome

Maria Vadalà,1,2 Valentina Sunseri Trapani,1 Giulia Guarrasi,1 Nicasio Ventura,1 Massimo Castellucci,1 Salvatore Cillino1 1Biomedicine, Neuroscience and Advanced Diagnostic Department, University of Palermo, Palermo, Italy; 2IEMEST, Euro-Mediterranean Institute of Science and Technology,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Vadalà M, Sunseri Trapani V, Guarrasi G, Ventura N, Castellucci M, Cillino S
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
Acceso en línea:https://doaj.org/article/0df633b46a2245c2b8035d9759a7fbe4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:0df633b46a2245c2b8035d9759a7fbe4
record_format dspace
spelling oai:doaj.org-article:0df633b46a2245c2b8035d9759a7fbe42021-12-02T11:23:05ZA Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome1177-5483https://doaj.org/article/0df633b46a2245c2b8035d9759a7fbe42020-09-01T00:00:00Zhttps://www.dovepress.com/a-real-world-study-of-dexamethasone-implant-in-treatment-naiumlve-pati-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Maria Vadalà,1,2 Valentina Sunseri Trapani,1 Giulia Guarrasi,1 Nicasio Ventura,1 Massimo Castellucci,1 Salvatore Cillino1 1Biomedicine, Neuroscience and Advanced Diagnostic Department, University of Palermo, Palermo, Italy; 2IEMEST, Euro-Mediterranean Institute of Science and Technology, Palermo, ItalyCorrespondence: Maria VadalàBiomedicine, Neuroscience and Advanced Diagnostic (BIND) Department, Ophthalmology Institute, University of Palermo, Palermo 90127, ItalyTel +39 091 6553909Email maria.vadala@unipa.itPurpose: There has been an increasing clinical interest in specific retinal parameters as non-invasive biomarkers of retinal inflammation in diabetic macular edema (DME) that have been shown to have prognostic value, such as hyperreflective retinal fields (HRFs) and subfoveal neuroretinal detachment (SND).Methods: We conducted a prospective, non-comparative study of treatment-naïve patients with DME to evaluate the efficacy of a Pro Re Nata (PRN) regimen of intravitreal dexamethasone implant 0.7 mg (DexI, Ozurdex™). After administration, patients underwent subsequent injections according to PRN criteria in case of edema relapse, but not earlier than 4 months after the previous treatment. Patients were evaluated at baseline, within 15 days of injection, and every month thereafter. During all visits, best-corrected visual acuity (BCVA) was recorded; central retinal thickness (CRT), type of edema, presence of SND, and presence and number of HRFs were evaluated using swept-source optical coherence tomography (SS-OCT) 3D. Treatment outcome was defined as changes in BCVA, CRT, SND and HRFs at 12 (T12) and 24 (T24) months compared with baseline (T0).Results: The study enrolled 24 eyes of 18 patients. The mean duration of follow-up was 18± 6.6 months; for all eyes, T12 data were available, while follow-up reached T24 for 12 eyes. BCVA improved significantly and CRT decreased significantly during treatment; the edema was no longer detectable in 13/24 eyes at T12 and 8/12 eyes at T24. No patient presented SND at T12 and T24, and the mean number of HRFs decreased significantly during treatment. Results with CRT and HRFs correlated with BCVA at 12 and 24 months. No significant adverse events were observed.Conclusion: In patients with DME, the intravitreal dexamethasone implant was effective and safe in improving both functional and tomographic parameters. This result is consistent with improvement in biomarkers of inflammation.Keywords: dexamethasone implant, diabetic macular edema, intravitreal implants, Ozurdex, real-world, inflammationVadalà MSunseri Trapani VGuarrasi GVentura NCastellucci MCillino SDove Medical Pressarticledexamethasone implantdiabetic macular edemaintravitreal implantsozurdexreal-worldinflammationOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 2657-2665 (2020)
institution DOAJ
collection DOAJ
language EN
topic dexamethasone implant
diabetic macular edema
intravitreal implants
ozurdex
real-world
inflammation
Ophthalmology
RE1-994
spellingShingle dexamethasone implant
diabetic macular edema
intravitreal implants
ozurdex
real-world
inflammation
Ophthalmology
RE1-994
Vadalà M
Sunseri Trapani V
Guarrasi G
Ventura N
Castellucci M
Cillino S
A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome
description Maria Vadalà,1,2 Valentina Sunseri Trapani,1 Giulia Guarrasi,1 Nicasio Ventura,1 Massimo Castellucci,1 Salvatore Cillino1 1Biomedicine, Neuroscience and Advanced Diagnostic Department, University of Palermo, Palermo, Italy; 2IEMEST, Euro-Mediterranean Institute of Science and Technology, Palermo, ItalyCorrespondence: Maria VadalàBiomedicine, Neuroscience and Advanced Diagnostic (BIND) Department, Ophthalmology Institute, University of Palermo, Palermo 90127, ItalyTel +39 091 6553909Email maria.vadala@unipa.itPurpose: There has been an increasing clinical interest in specific retinal parameters as non-invasive biomarkers of retinal inflammation in diabetic macular edema (DME) that have been shown to have prognostic value, such as hyperreflective retinal fields (HRFs) and subfoveal neuroretinal detachment (SND).Methods: We conducted a prospective, non-comparative study of treatment-naïve patients with DME to evaluate the efficacy of a Pro Re Nata (PRN) regimen of intravitreal dexamethasone implant 0.7 mg (DexI, Ozurdex™). After administration, patients underwent subsequent injections according to PRN criteria in case of edema relapse, but not earlier than 4 months after the previous treatment. Patients were evaluated at baseline, within 15 days of injection, and every month thereafter. During all visits, best-corrected visual acuity (BCVA) was recorded; central retinal thickness (CRT), type of edema, presence of SND, and presence and number of HRFs were evaluated using swept-source optical coherence tomography (SS-OCT) 3D. Treatment outcome was defined as changes in BCVA, CRT, SND and HRFs at 12 (T12) and 24 (T24) months compared with baseline (T0).Results: The study enrolled 24 eyes of 18 patients. The mean duration of follow-up was 18± 6.6 months; for all eyes, T12 data were available, while follow-up reached T24 for 12 eyes. BCVA improved significantly and CRT decreased significantly during treatment; the edema was no longer detectable in 13/24 eyes at T12 and 8/12 eyes at T24. No patient presented SND at T12 and T24, and the mean number of HRFs decreased significantly during treatment. Results with CRT and HRFs correlated with BCVA at 12 and 24 months. No significant adverse events were observed.Conclusion: In patients with DME, the intravitreal dexamethasone implant was effective and safe in improving both functional and tomographic parameters. This result is consistent with improvement in biomarkers of inflammation.Keywords: dexamethasone implant, diabetic macular edema, intravitreal implants, Ozurdex, real-world, inflammation
format article
author Vadalà M
Sunseri Trapani V
Guarrasi G
Ventura N
Castellucci M
Cillino S
author_facet Vadalà M
Sunseri Trapani V
Guarrasi G
Ventura N
Castellucci M
Cillino S
author_sort Vadalà M
title A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome
title_short A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome
title_full A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome
title_fullStr A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome
title_full_unstemmed A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome
title_sort real-world study of dexamethasone implant in treatment-naïve patients with diabetic macular edema: efficacy and correlation between inflammatory biomarkers and treatment outcome
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/0df633b46a2245c2b8035d9759a7fbe4
work_keys_str_mv AT vadalam arealworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
AT sunseritrapaniv arealworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
AT guarrasig arealworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
AT venturan arealworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
AT castelluccim arealworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
AT cillinos arealworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
AT vadalam realworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
AT sunseritrapaniv realworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
AT guarrasig realworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
AT venturan realworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
AT castelluccim realworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
AT cillinos realworldstudyofdexamethasoneimplantintreatmentnaiumlvepatientswithdiabeticmacularedemaefficacyandcorrelationbetweeninflammatorybiomarkersandtreatmentoutcome
_version_ 1718395921705730048